Tharimmune Inc. Stock Analysis THAR

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 2 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. The company has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The company is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The firm is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.